Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical on track with Alzheimer drug trial

Actinogen Medical on track with Alzheimer drug trial

Alzheimer’s disease drug developer Actinogen Medical (ASX:ACW) is on a path to the second critical phase of its clinical trial with its promising new treatment for patients with alzheimer's dementia.

Its novel drug compound Xanamen targets the enzyme 11beta-HSD1 blocking production of excess cortisol and negative effects of elevated levels.

The trial which is being conducted in Perth saw Xanamen effectively delivered by oral administration to the brain in doses that are predicted to inhibit the 11beta-HSD1 enzyme in the brain in patients.

Cortisol is known as the “stress hormone”, and excess cortisol in the brain is associated with memory loss, amyloid plaquing and neural death, the hallmarks of Alzheimer’s disease.

With the results, Actinogen Medical will move to a Phase II trial to demonstrate the effectiveness of Xanamem in treating patients suffering from mild Alzheimer’s disease.

The second phase of the trial will treat around 200 patients in Australia, the UK and the USA, under a U.S. Food & Drug Administration (FDA) approved Investigational New Drug (IND).

The prize for a successful drug is significant with a multi-billion dollar market potential. The cost of alzheimer’s treatment in the US alone was estimated to be US$250 billion in 2013, with this cost estimated to increase to US$1 trillion by 2050.

Alzheimer’s disease is now the second leading cause of death in Australia.

Actinogen is fully funded for its pivotal Phase II clinical trial. 

Positive results from this Phase II trial could see a significant partnering potential given the interest in alzheimers from pharmaceutical companies. 

In late September, 24 million shares were traded in the company in one day.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.





Register here to be notified of future ACW Company articles
View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

cancer cells
July 12 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use